236 related articles for article (PubMed ID: 18775673)
1. Cancer stem cells, CD200 and immunoevasion.
Kawasaki BT; Farrar WL
Trends Immunol; 2008 Oct; 29(10):464-8. PubMed ID: 18775673
[TBL] [Abstract][Full Text] [Related]
2. Immunology of cancer stem cells in solid tumours. A review.
Maccalli C; Volontè A; Cimminiello C; Parmiani G
Eur J Cancer; 2014 Feb; 50(3):649-55. PubMed ID: 24333096
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.
Ruiu R; Tarone L; Rolih V; Barutello G; Bolli E; Riccardo F; Cavallo F; Conti L
Prog Mol Biol Transl Sci; 2019; 164():119-188. PubMed ID: 31383404
[TBL] [Abstract][Full Text] [Related]
4. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.
Pan Q; Li Q; Liu S; Ning N; Zhang X; Xu Y; Chang AE; Wicha MS
Stem Cells; 2015 Jul; 33(7):2085-92. PubMed ID: 25873269
[TBL] [Abstract][Full Text] [Related]
5. The role of CD200-CD200R in tumor immune evasion.
Liao KL; Bai XF; Friedman A
J Theor Biol; 2013 Jul; 328():65-76. PubMed ID: 23541619
[TBL] [Abstract][Full Text] [Related]
6. The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure.
Galassi C; Musella M; Manduca N; Maccafeo E; Sistigu A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572009
[TBL] [Abstract][Full Text] [Related]
7. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.
Hirohashi Y; Torigoe T; Inoda S; Takahashi A; Morita R; Nishizawa S; Tamura Y; Suzuki H; Toyota M; Sato N
Immunotherapy; 2010 Mar; 2(2):201-11. PubMed ID: 20635928
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche.
Rajayi H; Tavasolian P; Rezalotfi A; Ebrahimi M
Int Rev Immunol; 2019; 38(6):267-283. PubMed ID: 31578892
[TBL] [Abstract][Full Text] [Related]
9. Macrophages and cancer stem cells: a malevolent alliance.
Allavena P; Digifico E; Belgiovine C
Mol Med; 2021 Sep; 27(1):121. PubMed ID: 34583655
[TBL] [Abstract][Full Text] [Related]
10. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.
Ames E; Canter RJ; Grossenbacher SK; Mac S; Chen M; Smith RC; Hagino T; Perez-Cunningham J; Sckisel GD; Urayama S; Monjazeb AM; Fragoso RC; Sayers TJ; Murphy WJ
J Immunol; 2015 Oct; 195(8):4010-9. PubMed ID: 26363055
[TBL] [Abstract][Full Text] [Related]
11. [Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy].
Miyamoto S; Kanaseki T; Hirohashi Y; Tsukahara T; Kikuchi Y; Sato N; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):40-47. PubMed ID: 28539553
[TBL] [Abstract][Full Text] [Related]
12. DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells.
Koshio J; Kagamu H; Nozaki K; Saida Y; Tanaka T; Shoji S; Igarashi N; Miura S; Okajima M; Watanabe S; Yoshizawa H; Narita I
Cancer Immunol Immunother; 2013 Oct; 62(10):1619-28. PubMed ID: 23974721
[TBL] [Abstract][Full Text] [Related]
13. A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties.
Mahmoodi S; Nezafat N; Negahdaripour M; Ghasemi Y
Curr Mol Med; 2019; 19(1):2-11. PubMed ID: 30714514
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies against human cancer stem cells.
Naujokat C
Immunotherapy; 2014; 6(3):290-308. PubMed ID: 24762074
[TBL] [Abstract][Full Text] [Related]
15. CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.
Chen J; Ding P; Li L; Gu H; Zhang X; Zhang L; Wang N; Gan L; Wang Q; Zhang W; Hu W
Stem Cell Reports; 2017 Jan; 8(1):140-151. PubMed ID: 28017655
[TBL] [Abstract][Full Text] [Related]
16. The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy.
Fábián Á; Vereb G; Szöllősi J
Cytometry A; 2013 Jan; 83(1):62-71. PubMed ID: 22997049
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to human cancer stem-like cells/cancer-initiating cells.
Hirohashi Y; Torigoe T; Tsukahara T; Kanaseki T; Kochin V; Sato N
Cancer Sci; 2016 Jan; 107(1):12-7. PubMed ID: 26440127
[TBL] [Abstract][Full Text] [Related]
18. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
Podnos A; Clark DA; Erin N; Yu K; Gorczynski RM
Breast Cancer Res Treat; 2012 Nov; 136(1):117-27. PubMed ID: 23053647
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?
Dunning NL; Laversin SA; Miles AK; Rees RC
Cancer Immunol Immunother; 2011 Aug; 60(8):1181-93. PubMed ID: 21688178
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy targeting cancer stem cells].
Kawakami Y; Matsushita M; Ueda R; Tsukamoto N; Ohta S
Nihon Rinsho; 2012 Dec; 70(12):2142-6. PubMed ID: 23259387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
